✦ Syn2bio: The Bet Handed to ShareholdersThin moat

Synektik (SNT) — the future bets

Synektik gave its loss-making research unit to its shareholders, and the market now values it at twice the demerger price.

Synektik's most speculative project is no longer Synektik's. Its cardiotracer, a radiopharmaceutical for heart perfusion imaging, and its search for new molecules were split off into Syn2bio S.A.: the extraordinary general meeting approved the demerger on 19 March 2026 and it was registered on 27 March, with shareholders receiving Syn2bio shares one for one1.

Syn2bio value (zł m)304,5Fair value at demerger, Mar 2026593,6Market value, Sep 202643,2Net assets transferredSynektik interim report to June 2026; stockanalysis
Priced at about twice the demerger value.

The accounts record what was given away. The distribution was valued at 304,5 million złoty, 35,70 złoty per Synektik share2, against net assets of 43,2 million złoty transferred3, producing a demerger gain of 261,3 million złoty4. In May 2025 the board had earmarked 50 million złoty for the business being separated5. The unit had lost 23,1 million złoty in the year to September 2025, shown as discontinued operations6.

For Synektik the effect is cleaner earnings: continuing net profit was 126,0 million złoty in that year against 102,9 million złoty in total7. For shareholders it was a second holding. Syn2bio traded at 68,00 złoty in September 2026, a market value of 593,58 million złoty8.

The research unit had become a large cost. Its segment, the new molecules research centre, lost 28,2 million złoty at the operating level in the year to September 2025, against 19,9 million złoty a year earlier9, and was running multi-centre clinical trials of the cardiotracer in Western Europe10.

For Synektik's own shareholders the measure is Syn2bio's market value. It is now a separate bet, owned directly and priced daily.

Moat trajectory: Widening

Syn2bio's market value is about twice its demerger value.

The number that tests this moat
Reported
Syn2bio market value
593,58m zł in Sep 2026 (304,5m zł at demerger)

The research bet now priced on its own.

Source: Syn2bio market data (stockanalysis) ↗
References
  1. ReportedIts cardiotracer, a radiopharmaceutical for heart perfusion imaging, and its search for new molecules were split off into Syn2bio S.A.: the extraordinary general meeting approved the demerger on 19 March 2026 and it was registered on 27 March, with shareholders receiving Syn2bio shares one for one.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - the demerger of Syn2bio, shareholders and group structure. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  2. ReportedThe distribution was valued at 304,5 million złoty, 35,70 złoty per Synektik share, against net assets of 43,2 million złoty transferred, producing a demerger gain of 261,3 million złoty.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - the demerger of Syn2bio, shareholders and group structure. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  3. ReportedThe distribution was valued at 304,5 million złoty, 35,70 złoty per Synektik share, against net assets of 43,2 million złoty transferred, producing a demerger gain of 261,3 million złoty.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - the demerger of Syn2bio, shareholders and group structure. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  4. ReportedThe distribution was valued at 304,5 million złoty, 35,70 złoty per Synektik share, against net assets of 43,2 million złoty transferred, producing a demerger gain of 261,3 million złoty.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - the demerger of Syn2bio, shareholders and group structure. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  5. ReportedIn May 2025 the board had earmarked 50 million złoty for the business being separated.
    Synektik annual management board report for the fiscal year to 30 September 2025 - financial review: margins, net debt, return on equity, working capital and deferred income. — October 2024 - September 2025 · publ. December 2025 · source ↗
  6. ReportedThe unit had lost 23,1 million złoty in the year to September 2025, shown as discontinued operations.
    Synektik Group audited consolidated financial statements for the fiscal year to 30 September 2025 (ESEF package) - revenue, costs, continuing and discontinued profit, earnings per share, segment note, cash flow. — October 2024 - September 2025 · publ. December 2025 · source ↗
  7. ReportedFor Synektik the effect is cleaner earnings: continuing net profit was 126,0 million złoty in that year against 102,9 million złoty in total.
    Synektik Group audited consolidated financial statements for the fiscal year to 30 September 2025 (ESEF package) - revenue, costs, continuing and discontinued profit, earnings per share, segment note, cash flow. — October 2024 - September 2025 · publ. December 2025 · source ↗
  8. ReportedSyn2bio traded at 68,00 złoty in September 2026, a market value of 593,58 million złoty.
    Syn2bio S.A. (WSE: S2B) market data - share price 68,00 złoty and market value 593,58 million złoty, September 2026. — September 2026 · publ. 23 September 2026 · source ↗
  9. ReportedIts segment, the new molecules research centre, lost 28,2 million złoty at the operating level in the year to September 2025, against 19,9 million złoty a year earlier, and was running multi-centre clinical trials of the cardiotracer in Western Europe.
    Synektik Group audited consolidated financial statements for the fiscal year to 30 September 2025 (ESEF package) - revenue, costs, continuing and discontinued profit, earnings per share, segment note, cash flow. — October 2024 - September 2025 · publ. December 2025 · source ↗
  10. ReportedIts segment, the new molecules research centre, lost 28,2 million złoty at the operating level in the year to September 2025, against 19,9 million złoty a year earlier, and was running multi-centre clinical trials of the cardiotracer in Western Europe.
    Synektik management board report for the half-year 1 October 2025 - 31 March 2026 - including the HistoSonics Edison exclusive distribution agreement and the installed base at March 2026. — October 2025 - March 2026 · publ. June 2026 · source ↗
Sources
Generated September 24, 2026